rosiglitazone has been researched along with alendronate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fantus, IG; Grynpas, MD; Renlund, R; Sardone, LD; Willett, TL | 1 |
| Fitzpatrick, LA; Guldberg, RE; Hoffman, SJ; Jolette, J; Kumar, S; Mansell, P; Samadfam, R; Smith, SY | 1 |
1 review(s) available for rosiglitazone and alendronate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for rosiglitazone and alendronate
| Article | Year |
|---|---|
Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Female; Hypoglycemic Agents; Insulin Resistance; Osteoporosis; Rats; Rosiglitazone; Thiazolidinediones | 2011 |
The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Time Factors; X-Ray Microtomography | 2013 |